Management

Officers, Directors and Principal Investigators

Dr. Goldberg was formerly a faculty member at Harvard Medical School, Boston, MA, Radiation Oncologist-in-Chief for the North Shore-LIJ Health System, New Hyde Park, NY, and Professor at the Albert Einstein College of Medicine, Bronx, NY. He has made seminal contributions in the field of HGF.
Dr. Yamin received his Ph.D. from The Rockefeller University, and has worked in small biopharma companies including Alteon, Mojave Therapeutics, Warren Pharmaceuticals and Araim Pharmaceuticals, in the areas of intellectual property, discovery and pre-clinical development. He is also a registered patent agent.
Dr. Narayan received his doctorate from The Ohio State University and conducted postdoctoral research at University of Wisconsin-Madison. He is an expert in models of acute tissue injury and chronic degenerative disease and is the recipient of multiple NIH, DoD and NSF translational research awards. He is a member of the Baltimore PKD Organization and an expert panelist for the European Society of Translational Medicine.
Dr. Panicker received his training at the Indian Institute of Science, Bangalore, India and at the University of Mississippi, Oxford, MS. He has had over 15 years of industry experience including senior positions at Recon, Shasun, Rhodia Chirex and OSI Pharmaceuticals. Dr Panicker is an expert in rational drug design and medicinal chemistry.
Dr. Oehlen received his doctorate from the University of Amsterdam in the Netherlands and was a post doctoral fellow at Rockefeller University in New York City. He has had over 10 years of industry experience working previously at Cadus Pharmaceuticals and OSI Pharmaceuticals. Dr. Oehlen has expertise in the areas of drug development and pulmonary diseases.
Dr. Smith received his training at SUNY-Stony Brook, NY, Rockefeller University, NY and the Roche Institute of Molecular Biology, NJ. He was formerly a senior scientist at OSI Pharmaceuticals. Dr. Smith has extensive expertise in drug discovery and neuroscience.
Dr. Paka received her Ph.D. degree from Osmania University, India, and pursued post-doctoral research on atherosclerotic cardiovascular disease for four years at Columbia University, NY. With extensive experience in the areas of cell biology and biochemistry, she plays a major role in the establishment of acute and chronic preclinical models to evaluate candidate compounds in organ-specific models of tissue injury. She is also a recipient of several translational research NIH awards.